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Objectives
The aim of the study was to establish a methodology for evaluating the hepatitis C continuum of
care in HIV/hepatitis C virus (HCV)-coinfected individuals and to characterize the continuum in
Europe on 1 January 2015, prior to widespread access to direct-acting antiviral (DAA) therapy.
Methods
Stages included in the continuum were as follows: anti-HCV antibody positive, HCV RNA tested,
currently HCV RNA positive, ever HCV RNA positive, ever received HCV treatment, completed HCV
treatment, follow-up HCV RNA test, and cure. Sustained virological response (SVR) could only be
assessed for those with a follow-up HCV RNA test and was defined as a negative HCV RNA result
measured > 12 or 24 weeks after stopping treatment.
Results
Numbers and percentages for the stages of the HCV continuum of care were as follows: anti-HCV
positive (n = 5173), HCV RNA tested (4207 of 5173; 81.3%), currently HCV RNA positive (3179 of
5173; 61.5%), ever HCV RNA positive (n = 3876), initiated HCV treatment (1693 of 3876; 43.7%),
completed HCV treatment (1598 of 3876; 41.2%), follow-up HCV RNA test to allow SVR
assessment (1195 of 3876; 30.8%), and cure (629 of 3876; 16.2%). The proportion that achieved
SVR was 52.6% (629 of 1195). There were significant differences between regions at each stage of
the continuum (P < 0.0001).
Conclusions
In the proposed HCV continuum of care for HIV/HCV-coinfected individuals, we found major gaps
at all stages, with almost 20% of anti-HCV-positive individuals having no documented HCV RNA
test and a low proportion achieving SVR, in the pre-DAA era.
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Introduction
Chronic hepatitis C virus (HCV) infection is a major glo-
bal health concern, with over 71 million people infected
world-wide [1]. Among an estimated 14 million people
living with HCV infection in the World Health Organiza-
tion (WHO) European Region [1], 711 500 are also coin-
fected with HIV [2]. The burden of HIV/HCV coinfection
is particularly high in Eastern Europe and Central Asia
where injecting drug use is the main mode of HIV trans-
mission [3]. In HIV/HCV-coinfected populations with
access to combination antiretroviral therapy (cART),
liver-related death has become one of the leading causes
of death [4].
While the goal of HIV treatment is long-term viral sup-
pression, HCV infection is curable. Until 2014, the stan-
dard-of-care HCV therapy was pegylated interferon (IFN)
in combination with ribavirin (RIB). This resulted in cure
rates, also known as sustained virological response (SVR),
between 40 and 80% depending on the HCV genotype
[5]. However, in HIV/HCV-coinfected individuals, treat-
ment success was lower, ranging from 29% for genotype
1 to 62% for genotype 2/3 [6]. As a consequence of the
toxicity of and contraindications for interferon (IFN)-
based therapy, treatment was often not given to those
most in need [7].
The introduction of new effective and well-tolerated
direct-acting antivirals (DAAs) to treat HCV infection can
lead to SVR in > 95% of cases [8]. While DAAs are
highly efficacious, they are also very costly [5], which is
currently limiting access to treatment [9]. Therefore, the
benefits of the new and improved HCV treatment will not
be realized unless barriers to care can be addressed.
A continuum of care (CoC) is a framework that
describes the successive steps in health care required for
individuals to go through to achieve optimal health out-
comes [10]. The HIV continuum has become an integral
public health tool for evaluating the outcome of HIV pro-
grammes, from diagnosis, to linkage to care, initiation of
antiretroviral therapy and virological suppression [11,12].
The care continuum is not limited to HIV, however, and
can be constructed for other conditions, such as HCV
infection [10,13]. The WHO has set the goal of eliminat-
ing viral hepatitis as a public health threat by 2030 [1].
This requires a reduction in new infections by 90% and a
reduction in mortality caused by viral hepatitis by 65%
compared with 2015 estimates [1]. HIV/HCV-coinfected
persons are considered a group with a high priority for
HCV therapy [1]. Reaching this ambitious goal requires a
huge effort to increase testing, linkage to care and access
to effective antiviral therapy [1]. Therefore, an HCV CoC
is an essential framework to predict, monitor and
evaluate progress in achieving these targets and allows
cross-country or population comparisons. A CoC can also
be used to identify leaks/breaks in HCV care that need to
be addressed in order to ensure individuals’ transition
through all stages and achievement of SVR. Several dif-
ferent HCV care continuums have been proposed for both
HCV-monoinfected [13–15] and HIV/HCV-coinfected
individuals [16–19]. While none of the steps in the HCV
continuum of care are unique to HIV/HCV-coinfected
individuals, the optimal design of a CoC might be differ-
ent for coinfected individuals already linked to specialist
HIV care. However, proposed continuums for coinfected
individuals use diverse methodology [16,17]. More work
is therefore required to develop a standardized CoC for
HCV-infected people living with HIV.
The objectives of this study were therefore to establish
a methodology for analysing the HCV CoC and apply it
to the EuroSIDA observational HIV-infected cohort in
order to identify key points of clinical HCV management
in 2015 across Europe, with a focus on regional differ-
ences.
Methods
EuroSIDA study participants
EuroSIDA is a large ongoing prospective observational
cohort study that began enrolling HIV-1-positive patients
in 1994. There are currently data on over 22 000 HIV-
positive individuals aged ≥ 16 years from 100 centres in
36 European countries, Israel and Argentina. These coun-
tries were categorized into regions, as in previous publi-
cations [20]:
• South: Greece, Israel, Italy, Portugal, Spain and Argen-
tina.
• Central-West: Austria, Belgium, France, Germany, Lux-
embourg and Switzerland.
• North: Denmark, Finland, Iceland, Ireland, the Nether-
lands, Norway, Sweden and the UK.
• Central-East: Bosnia-Herzegovina, Croatia, Czech
Republic, Hungary, Poland, Romania, Serbia, Slovakia
and Slovenia.
• East: Belarus, Estonia, Georgia, Latvia, Lithuania,
Russia and Ukraine.
To ensure that the EuroSIDA study population is repre-
sentative of the current HIV-infected population in
Europe, new cohorts are enrolled at regular intervals. To
date, 10 patient cohorts have been recruited since 1994.
For each cohort, a predefined number of patients were
enrolled from each site. While individuals in cohorts 1 to
9 were enrolled irrespective of HCV status, HIV-positive
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individuals in cohort 10 were also required to be anti-HCV
positive (HCV RNA positive or negative). From 1 June
2014 to 31 December 2016, 4034 consecutive patients
were enrolled into cohort 10. The consecutive enrolment
of unselected individuals ensures that participants with
irregular follow-up are not excluded from the study. Data
are collected prospectively at clinical sites and sent at 12-
monthly intervals (6-monthly until 2015) to the EuroSIDA
coordinating centre, which is based at the Centre of Excel-
lence for Health, Immunity and Infections (CHIP). Individ-
uals are considered lost to follow-up (LTFU) if they do not
have a CD4 count measurement, HIV RNA measurement or
clinic visit for 12 months. The number of individuals LTFU
annually is quite low, with Mocroft et al. [21] reporting
the incidence of LTFU at 3.72 per 100 person-years of fol-
low-up (PYFU), with variation across countries. If an indi-
vidual has no reported data for > 1 year, the clinic is
queried. If there is no record of a clinic visit by 2 and
5 years, then the clinic is queried again. Participants
continue to be followed up if they transfer to another
EuroSIDA clinic. Further details on the EuroSIDA cohort
have been reported elsewhere [22].
Anti-HCV status and HCV RNA status have been col-
lected since 1997, when the central plasma repository was
set up which receives plasma from most individuals
enrolled in EuroSIDA every 6 months. In 2006, individuals
with stored plasma samples and unknown hepatitis B and
C status were centrally tested for anti-HCV antibodies,
HCV RNA, genotype and hepatitis B and D markers. Euro-
SIDA has also collected HCV treatment start and stop dates
since 1997; however, since cohort 10, HCV treatment
dosage, adherence, treatment-limiting adverse events, and
the reason for discontinuing treatment have also been col-
lected for HIV/HCV-coinfected individuals. Further infor-
mation on the collection of anti-HCV, HCV RNA and
genotype data has been detailed elsewhere [23,24].
We included all anti-HCV-positive individuals who were
under follow-up (FU) on 1 January 2015 (last visit 1 Jan-
uary 2014 or later); the index date was defined as 1 Jan-
uary 2015. Baseline characteristics were defined based on
the most recent measurement before the index date; indi-
viduals without a CD4 count or HIV viral load measured
prior to the index date had a value up to 6 months after
the index date included, if available. The most recent
fibrosis marker measured prior to the index date was used
to determine whether the individual had advanced fibrosis
(METAVIR ≥ F3), which was defined using a consensus
definition [25]. When more than one fibrosis marker was
measured on the same day, then priority was given to a
biopsy result, followed by a FibroScan result, an aspartate
aminotransferase/platelet ratio index (APRI) score then
finally a plasma hyaluronic acid result. Information on
how fibrosis data are collected and defined in EuroSIDA
has been specified elsewhere [4].
Definition of continuum of care stages
All stages of the continuum are defined in Table 1. Indi-
viduals who satisfied the inclusion criteria of being under
follow-up and anti-HCV positive prior to 1 January 2015
were included in this analysis (stage 1). The number of
anti-HCV-positive individuals who were HCV RNA tested
before the index date (stage 2) and currently HCV RNA
positive (stage 3) was then determined. Those ever HCV
RNA positive prior to the index date were included in
stage 4, and the proportions who initiated treatment
before the index date (stage 5), completed treatment
before the index date (stage 6), had a follow-up HCV
RNA test after completing treatment (stage 7), and
achieved cure (stage 8) were also determined. SVR could
only be assessed for those with a follow-up HCV RNA
test which was defined as an HCV RNA negative result
measured > 12 or 24 weeks (for IFN-free or IFN-based
regimens, respectively) after stopping treatment.
Depending on the denominator, the term ‘cure’ or ‘SVR’
is used in this paper. ‘Cure’ indicates the number of indi-
viduals with a negative HCV RNA test at > 12 or 24 weeks
post-treatment among all individuals ever HCV RNA
Table 1 Hepatitis C virus (HCV) continuum of care definitions
Stage Definition
Stage 1: anti-HCV positive Anti-HCV antibody-positive test, HCV RNA
positive, HCV genotyped or received HCV
treatment before index date
Stage 2: ever HCV
RNA tested
HCV RNA tested, HCV genotyped or received
HCV treatment before index date
Stage 3: currently
HCV RNA positive
Most recent HCV RNA test before index date
was positive, HCV genotyped but not
treated before index date, started treatment
for the first time after index date or the
first HCV RNA test result after index date
is positive and never treated
Stage 4: ever HCV
RNA positive
HCV-RNA-positive test, received HCV
treatment or HCV genotyped before
index date
Stage 5: ever received
treatment
Started HCV treatment on or before
index date
Stage 6: treatment
completed
Completed HCV treatment on or before
index date
Stage 7: FU HCV
RNA available
HCV RNA test > 12 or 24 weeks after
completing treatment (for IFN-free and
IFN-based therapy, respectively). HCV RNA
test data included for duration of FU to
allow for assessment of SVR
Stage 8: cured HCV-RNA-negative test at least 12 or 24 weeks
post-treatment (for IFN-free and IFN-based
therapy, respectively)
FU, follow-up; IFN, interferon; SVR, sustained virological response.
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positive, while ‘SVR’ is used to describe the same number,
but among those who have received HCV treatment and
have a follow-up HCV RNA test for SVR assessment.
Statistical analysis
Baseline characteristics were compared between regions
using v2 and Kruskal–Wallis tests for categorical and
continuous variables, respectively. SAS 9.4 was used for
all analyses (version 9.4; SAS Institute, Cary, NC).
Results
Patient characteristics
Among 12 791 HIV-positive individuals under follow-up
in EuroSIDA on 1 January 2015, 12 534 (98%) had been
tested for anti-HCV, and, of them, 5173 (41%) were anti-
HCV positive and included in these analyses. Of the 5173
anti-HCV-positive individuals, 1294 (25%), 1170 (23%),
679 (13%), 763 (15%) and 1267 (24%) were from South-
ern, Central-West, Northern, Central-East, and Eastern
Europe, respectively. Overall and regional characteristics
for those who were anti-HCV positive are shown in
Table 2; there were significant differences between regions
for all characteristics (P < 0.001). The overall study popu-
lation was mostly male (70%), ranging from 62% male in
Eastern Europe to 75% in Northern Europe. The median
age was 47 years [interquartile range (IQR) 39–53 years],
with a median age of 52 (IQR 47–56) years in Central-West
and a younger median age of 37 (IQR 33–42) years in
Eastern Europe. The most common route of HIV transmis-
sion was injecting drug use (IDU) in all regions. At least
89% of individuals in each region had an HIV viral load
< 500 HIV-1 RNA copies/mL, except in Eastern Europe
where only 62% of individuals were virally suppressed.
The median CD4 cell count was highest in the Central-
West region (593 cells/lL; IQR 409–809 cells/lL) and low-
est in Eastern Europe (427 cells/lL; IQR 276–589 cells/lL).
HCV genotype and fibrosis measurement
Of the 5173 individuals who were anti-HCV positive
before 1 January 2015, 4902 (94.8%) had a fibrosis mar-
ker; the most common marker was APRI score (78.9%)
followed by FibroScan (18.3%), liver biopsy (2.1%) and
hyaluronic acid (0.7%). Northern Europe had the lowest
proportion of individuals with a fibrosis marker (83.2%),
while Southern Europe had the highest (97.6%). Overall,
15.7% of those with a fibrosis marker had advanced
fibrosis or cirrhosis (METAVIR ≥ F3), with the burden of
≥ F3 fibrosis ranging from 13.1% in Central-East to
17.5% in Southern Europe. Among all anti-HCV-positive
individuals, 47.2% had been genotyped, with large
regional differences. Genotype 1 was the most common
genotype in all regions followed by genotype 3
(Table 2).
Continuum of HCV care among HIV/HCV-coinfected
individuals in Europe
Of the 5173 anti-HCV-positive individuals who were
included in this analysis, 4207 (81.3%) were HCV RNA
tested, and 3179 (61.5%) were HCV RNA positive on the
index date of 1 January 2015 (Fig. 1a). There were 3876
individuals with confirmed current or past positive HCV
RNA prior to 1 January 2015, of whom 1693 (43.7%)
had started HCV treatment, 1598 (41.2%) had completed
HCV treatment, and 1195 (30.8%) had an HCV RNA test
result after completing treatment (allowing for SVR
assessment) (Fig. 1b). Although 41% of all HCV-RNA-
positive individuals had completed HCV treatment, only
629 (16.2%) of the entire HCV-RNA-positive population
had confirmed HCV cure. However, 403 of 1598 (25%)
of all who had completed treatment had missing follow-
up HCV RNA for SVR assessment. The proportion of
individuals with SVR, of those who could have SVR
assessed, was 52.6% (629 individuals). Of all the individ-
uals who started HCV treatment, 84% received IFN +
Ribavirin (RBV), 9% IFN + DAA regimens, and 7% IFN-
free DAA regimens. The majority of individuals eligible
for SVR assessment had received IFN-based regimens
(95.3%), and genotypes 1 and 4 were the most common
genotypes (65%).
Regional differences in the continuum of care
There were significant differences between regions at
each stage of the continuum (P < 0.0001). The propor-
tion of anti-HCV-positive individuals who were HCV
RNA tested was > 90% in South, Central-West and
Northern Europe and lower in Central-East (84.9%) and
Eastern Europe (51.5%). The proportion of individuals
who had not started treatment after a positive HCV RNA
test result was consistently high across all regions. The
proportion of ever HCV-RNA-positive individuals who
completed treatment ranged from 48.4% (534 of 1103)
in Southern Europe to 33.2% (211 of 635) in Eastern
Europe, while the proportion of individuals who com-
pleted treatment with a follow-up HCV RNA test 12 or
24 weeks after completing treatment ranged from 65.6%
(300 of 457) in Central-West to 82.8% (147 of 211) in
Northern Europe. There were also large regional differ-
ences in the proportion of ever HCV-RNA-positive indi-
viduals with confirmed cure, ranging from 11.1% in
Central-Eastern Europe to 19.0% in Northern and
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Southern Europe. Among individuals cured, Northern
Europe also had the highest proportion of individuals
who had received DAA (IFN-free) treatment (15%). No
individuals in Central-East or Eastern Europe received
IFN-free regimens.
Discussion
We propose an eight-stage HCV CoC for HIV/HCV-coin-
fected individuals, which would allow cross-study compar-
isons for access and outcomes of HCV treatment in HIV/
HCV-coinfected individuals. This tool will allow the assess-
ment of improvements in services over time and highlight
gaps where individuals are not accessing appropriate care.
Lourenco et al. [27] make the case for a standardized
HIV continuum based on inconsistencies found in contin-
uums from the USA, Canada (British Columbia), France
and Denmark. For example, while all reported viral
suppression, the definitions varied greatly, meaning that
cross-study comparisons, an essential tool for monitoring,
were not feasible [27]. The differences highlight the
importance of a standardized continuum if comparisons
with different populations and time-points are to be made
confidently or if the impact of public health programmes
is to be measured [27]. While this point was emphasized
for the HIV continuum, it also stands in the HCV context.
Although we defined eight stages in this continuum,
more or fewer stages could be included depending on the
setting. However, it is important to ensure that key indi-
cators around diagnosis, treatment and cure are included
to monitor progress towards the WHO 2030 goals for
elimination of viral hepatitis as a public health threat [1].
As well as not estimating the undiagnosed population, we
did not include an accurate measure of ‘engagement in
care,’ which other HIV/HCV-coinfection continuums have
estimated [18]. This would be helpful to understand
Table 2 Characteristics of anti-hepatitis C virus (HCV)-positive individuals included in analysis overall and by region
Variable Overall South Central-West North Central-East East
n (%)
Overall 5173 (100.0) 1294 (25.0) 1170 (22.6) 679 (13.1) 763 (14.7) 1267 (24.5)
Sex
Male 3600 (69.6) 921 (71.2) 850 (72.6) 512 (75.4) 528 (69.2) 789 (62.3)
Female 1573 (30.4) 373 (28.8) 320 (27.4) 167 (24.6) 235 (30.8) 478 (37.7)
Ethnicity
White 4641 (89.7) 1202 (92.9) 969 (82.8) 454 (66.9) 751 (98.4) 1265 (99.8)
Fibrosis*
< F3 4131 (84.3) 1037 (82.1) 967 (85.2) 462 (81.8) 645 (86.6) 1020 (85.4)
≥ F3† 771 (15.7) 226 (17.9) 168 (14.8) 103 (18.2) 100 (13.4) 174 (14.6)
HCV genotype‡
1 1291 (52.8) 455 (54.7) 253 (59.1) 190 (56.7) 180 (39.6) 213 (53.9)
2 73 (3.0) 13 (1.6) 18 (4.2) 26 (7.8) 4 (0.9) 12 (3.0)
3 708 (29.0) 211 (25.4) 86 (20.1) 92 (27.5) 149 (32.8) 170 (43.0)
4 372 (15.2) 153 (18.4) 71 (16.6) 27 (8.1) 121 (26.7) 0 (0.0)
HIV risk group
MSM 933 (18.0) 211 (16.3) 316 (27.0) 247 (36.4) 134 (17.6) 25 (2.0)
IDU 2903 (56.1) 735 (56.8) 550 (47.0) 280 (41.2) 463 (60.7) 875 (69.1)
Heterosexual 980 (18.9) 231 (17.9) 208 (17.8) 98 (14.4) 100 (13.1) 343 (27.1)
Other 160 (3.1) 32 (2.5) 65 (5.6) 30 (4.4) 28 (3.7) 5 (0.4)
HIV RNA
< 500 copies/mL 4442 (85.9) 1238 (95.7) 1101 (94.1) 646 (95.1) 675 (88.5) 782 (61.7)
500–10 000 copies/mL 286 (5.5) 27 (2.1) 28 (2.4) 17 (2.5) 29 (3.8) 185 (14.6)
> 10 000 copies/mL 365 (7.1) 24 (1.9) 36 (3.1) 10 (1.5) 46 (6.0) 249 (19.7)
Ever received cART
No 369 (7.1) 42 (3.2) 35 (3.0) 41 (6.0) 30 (3.9) 221 (17.4)
Yes 4804 (92.9) 1252 (96.8) 1135 (97.0) 638 (94.0) 733 (96.1) 1046 (82.6)
Median (IQR)
Age (years) 47 (39–53) 50 (46–54) 52 (47–56) 51 (46–56) 41 (36–48) 37 (33–42)
CD4 count (cells/lL) 530 (363–748) 577 (402–808) 593 (409–806) 550 (393–785) 536.5 (375–733) 427 (276–589)
CD4 nadir (cells/lL) 177 (76–289) 166 (70–272) 155 (56–258) 149.5 (41–240) 182 (72–295) 221 (116–335)
There was evidence of regional differences for all variables (P < 0.0001).
*Calculated as a proportion of those with a liver fibrosis marker; fibrosis stage was missing for 271 (5.24%) overall; 31 (11.4%), 35 (12.9%), 114
(42.1%), 18 (6.6%) and 73 (26.9%) in South, Central-West, North, Central-East and Eastern Europe, respectively (P < 0.0001). †Either a biopsy
(≥ METAVIR stage F3), FibroScan (> 9.5 kPa), APRI (score > 1.5) [25] or hyaluronic acid level (> 160 ng/mL) [26] during follow-up. ‡Calculated as a
proportion of those genotyped; genotype was missing for 2729 (52.8%) overall; 462 (16.9%), 742 (27.2%), 344 (12.6%), 309 (11.3%) and 872 (32.0%)
in South, Central-West, North, Central-East and Eastern Europe, respectively (P < 0.0001).
cART, combination antiretroviral therapy; IDU, injecting drug use; MSM, men who have sex with men; APRI, aspartate aminotransferase/platelet ratio
index.
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whether patients are not transitioning through the stages
because of a lack of engagement or failures in health
structures so that interventions and resources can be tar-
geted at the appropriate area.
Other descriptions of HCV continuums included infor-
mation that we did not. For example, Hajarizadeh et al.
[13] included an estimate for the number of people living
with HCV in Australia and were therefore able to provide
an estimate of the proportion of individuals living with
HCV who were undiagnosed (25%). However, they did
not include information on individuals’ engagement in
care [13]. The Austrian HIV Cohorts Study developed a
continuum with similar stages to the continuum pre-
sented in this paper [19]. While they also did not estimate
the number of people living with HCV, their definition of
SVR allowed them to capture reinfections, which we did
not [19]. Cachay et al. [17] included stages in their con-
tinuum around engagement in care; however, as their
continuum is based on data from a single clinic, they also
did not include an estimate of the number of people liv-
ing with HCV. However, our proposed continuum has
some advantages over other descriptions of the HCV CoC,
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Fig. 1 Hepatitis C virus (HCV) continuum of care, by region. The figure shows the diagnostic (a) and treatment (b) stages of the continuum of
HCV care among HIV/HCV-coinfected individuals in different geographical regions of Europe. Overall values for each stage of the continuum
are shown above each stage, with percentages in parentheses. The v2 test provides evidence of regional difference at all stages (P < 0.0001).
†Individuals who had an follow-up (FU) HCV RNA test at least 12 or 24 weeks after completing treatment for interferon (IFN)-free and IFN-
based therapy, respectively.
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such as including information on the proportion of indi-
viduals that completed HCV treatment and the proportion
of individuals who were followed up after stopping treat-
ment, which provides insight into whether lack of
engagement with care is a potential reason for not
achieving SVR.
In our patient population of 5173 individuals coin-
fected with HIV and HCV from across Europe, there were
major gaps at all stages of our suggested hepatitis C CoC
at 1 January 2015, with significant disparities between
the different regions in Europe at each stage. Approxi-
mately 1 in 5 of those anti-HCV positive had no docu-
mented HCV RNA test. Less than half of those chronically
infected had initiated anti-HCV therapy and only 16.2%
had a documented HCV cure, which is partly attributable
to the lack of effective HCV therapy available at the time.
The proportion of individuals who were HCV RNA tested
varied greatly between regions. An HCV RNA test is rela-
tively expensive [28], and it is possible that in some set-
tings HCV RNA testing is primarily targeted at
individuals where HCV treatment is considered.
Among patients known to be HCV RNA positive, the
proportion who had received HCV treatment was highest
in Southern and Central-Western Europe and lower in
other regions. Although the proportion treated in North-
ern Europe was similar to that in Central-East and East-
ern Europe, fewer people had been HCV RNA tested in
Central-East and Eastern Europe. Although we have
focused on which stages might be needed in a hepatitis C
continuum, it is worth noting that, for descriptive pur-
poses, this continuum is based on January 2015, before
the widespread introduction of DAAs. In the interferon
era, therapy was often deferred because of contraindica-
tions, toxicities, low efficacy and the cost associated with
IFN-based therapy [29]. Alcohol consumption, current
IDU and having a pre-existing mental illness have been
identified as the main reasons for not initiating HCV
treatment; however, there is a lack of evidence to support
excluding patients for these reasons, with treatment
adherence better predicting SVR [30]. However, there are
still challenges in the DAA era; while The European
Association for the Study of the Liver (EASL) guidelines
for treating HCV infection recommend the prioritization
of HCV therapy for those with advanced liver fibrosis or
from high-risk groups [31], access to treatment is still
low because of high drug prices.
The proportion of individuals with a confirmed HCV
cure was low across all regions. These low cure rates
should also be viewed in the context that IFN plus RBV
was the predominant regimen in this study and that the
majority of the study population had genotype 1 or 4,
which are difficult to cure genotypes with IFN-based
regimens [32]. At the point of analysis, second-generation
DAAs had only been available for a short time, and
therefore DAA uptake was still low. Only 56 (4.7%) of the
1195 individuals with a follow-up HCV RNA test after
completing treatment received IFN-free treatment.
Nonetheless, we have already seen a rapid increase in
DAA uptake in 2014 and 2015 for all EuroSIDA regions
except Eastern Europe [33]. As DAAs are highly effective
for all genotypes [8], we expect to see SVR rates improv-
ing in the DAA era.
One of the main limitations of the study was the lack of
a follow-up HCV RNA measurement at least 12/24 weeks
after completing treatment, making it was impossible to
determine SVR for all patients. It is possible that HCV
RNA had been measured at a site other than an HIV clinic
and therefore not reported, although substantial efforts
have been made to follow up missing data from all sites
as part of the quality assurance programme in EuroSIDA.
There were also insufficient data on date of HCV diagno-
sis, meaning that it was not possible to look at late pre-
sentation in our analysis. Although cohorts are more
inclusive and allow more generalizable findings than clini-
cal trial populations [34], they are still not entirely repre-
sentative of all HCV-infected individuals as there are
vulnerable groups or incarcerated populations that are not
included in cohorts. This study did not estimate the undi-
agnosed population, which is an important part of the
continuum as one of the major breakpoints of the HCV
continuum is diagnosis. Our study also has a number of
important strengths, such as being one of the first studies
to suggest a comprehensive CoC for HCV- and HIV-coin-
fected individuals. The size of the study population, which
includes data from clinics all over Europe, is also a
strength, as other continuums only include data from a
single site, making the results less generalizable.
The method we propose for the HCV continuum was
applied to the IFN era and will allow us to evaluate the
effect of DAA therapy on transition through care at a
later date. The gaps and regional differences identified
emphasize the importance of assessing the treatment
landscape, developing strategies to reduce prevalence,
and establishing better standards of care for individuals
with both HIV and HCV infections, as well as emphasiz-
ing the importance of in-depth analyses of the reasons
for these gaps at the local level. The majority of coin-
fected individuals are injecting drug users [1], which
means that they also face social issues such as stigma
and marginalization which act as barriers to care [35].
Therefore, work on removing barriers to care and estab-
lishing a meaningful continuum is essential if the goal of
eliminating viral hepatitis as a public health threat by
2030 [1] is to be met.
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Appendix : The multi-centre EuroSIDA study
group (national coordinators in
parentheses)
Argentina: (M. Losso), M. Kundro, Hospital J. M. Ramos
Mejia, Buenos Aires. Austria: (B Schmied), Otto Wagner
Hospital, Vienna; R. Zangerle, Medical University
Innsbruck, Innsbruck. Belarus: (I. Karpov), A. Vassilenko,
Belarus State Medical University, Minsk, V.M. Mitsura,
Gomel State Medical University, Gomel; D. Paduto,
Regional AIDS Centre, Svetlogorsk. Belgium: (N.
Clumeck), S. De Wit, M. Delforge, Saint-Pierre Hospital,
Brussels; E. Florence, Institute of Tropical Medicine,
Antwerp; L. Vandekerckhove, University Ziekenhuis Gent,
Gent. Bosnia-Herzegovina: (V. Hadziosmanovic), Klinicki
Centar Univerziteta Sarajevo, Sarajevo. Croatia: (J.
Begovac), University Hospital of Infectious Diseases,
Zagreb. Czech Republic: (L. Machala), D. Jilich, Faculty
Hospital Bulovka, Prague; D. Sedlacek, Charles University
Hospital, Plzen. Denmark: G. Kronborg, T. Benfield,
Hvidovre Hospital, Copenhagen; J. Gerstoft, T.
Katzenstein, Rigshospitalet, Copenhagen; C. Pedersen, I.S.
Johansen, Odense University Hospital, Odense; L.
Ostergaard, Skejby Hospital, Aarhus, L. Wiese, N.F.
Moller, Sjællands Universitetshospital, Roskilde; L.N.
Nielsen, Hillerod Hospital, Hillerod. Estonia: (K. Zilmer),
West-Tallinn Central Hospital, Tallinn; Jelena Smidt,
Nakkusosakond Siseklinik, Kohtla-J€arve. Finland: (M Ris-
tola), I. Aho, Helsinki University Central Hospital, Hel-
sinki. France: (J-P Viard), Ho^tel-Dieu, Paris; P.-M .Girard,
Hospital Saint-Antoine, Paris; C. Pradier, E. Fontas,
Ho^pital de l’Archet, Nice; .C Duvivier, Ho^pital Necker-
Enfants Malades, Paris. Germany: (J Rockstroh), Univer-
sit€ats Klinik Bonn; G. Behrens, Medizinische Hochschule
Hannover; O. Degen, University Medical Center
Hamburg-Eppendorf, Infectious Diseases Unit, Hamburg;
H.J. Stellbrink, IPM Study Center, Hamburg; C. Stefan,
JW Goethe University Hospital, Frankfurt; J. Bogner,
Medizinische Poliklinik, Munich; G. F€atkenheuer, Univer-
sit€at K€oln, Cologne. Georgia: (N. Chkhartishvili) Infectious
Diseases, AIDS & Clinical Immunology Research Center,
Tbilisi. Greece: (P. Gargalianos), G. Xylomenos, K.
Armenis, Athens General Hospital ‘G Gennimatas’; H.
Sambatakou, Ippokration General Hospital, Athens. Hun-
gary: (J. Szlavik), Szent Laslo Hospital, Budapest. Iceland:
(M. Gottfredsson), Landspitali University Hospital, Reyk-
javik. Ireland: (F. Mulcahy), St. James’s Hospital, Dublin.
Israel: (I. Yust), D. Turner, M. Burke, Ichilov Hospital, Tel
Aviv; E. Shahar, G. Hassoun, Rambam Medical Center,
Haifa; H. Elinav, M. Haouzi, Hadassah University Hospi-
tal, Jerusalem; D. Elbirt, Z.M. Sthoeger, AIDS Center
(Neve Or), Jerusalem. Italy: (A D’Arminio Monforte), Isti-
tuto Di Clinica Malattie Infettive e Tropicale, Milan; R.
Esposito, I. Mazeu, C. Mussini, Universita Modena,
Modena; F. Mazzotta, A. Gabbuti, Ospedale S Maria
Annunziata, Firenze; V. Vullo, M. Lichtner, University di
Roma la Sapienza, Rome; M. Zaccarelli, A. Antinori, R.
Acinapura, M. Plazzi, Istituto Nazionale Malattie Infettive
Lazzaro Spallanzani, Rome; A. Lazzarin, A. Castagna, N.
Gianotti, Ospedale San Raffaele, Milan; M. Galli, A.
Ridolfo, Osp. L. Sacco, Milan. Latvia: (B. Rozentale),
Infectology Centre of Latvia, Riga. Lithuania: (V. Uzdavi-
niene) Vilnius University Hospital Santaros Klinikos, Vil-
nius; R. Matulionyte, Centro poliklinika, Vilnius, Vilnius
University Hospital Santaros Klinikos, Vilnius. Luxem-
bourg: (T. Staub), R. Hemmer, Centre Hospitalier, Luxem-
bourg. Netherlands: (P. Reiss), Academisch Medisch
Centrum bij de Universiteit van Amsterdam, Amsterdam.
Norway: (D.H. Reikvam), A. Maeland, J. Bruun, Oslo
University Hospital, Ullevaal. Poland: (B. Knysz), J.
Gasiorowski, M. Inglot, Medical University, Wroclaw; E.
Bakowska, Centrum Diagnostyki i Terapii AIDS, Warsaw;
R. Flisiak, A. Grzeszczuk, Medical University, Bialystok;
M. Parczewski, K. Maciejewska, B. Aksak-Was , Medical
University, Szczecin; M. Beniowski, E. Mularska, Osrodek
Diagnostyki i Terapii AIDS, Chorzow; T. Smiatacz, M.
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Gensing, Medical University, Gdansk; E. Jablonowska, J.
Kamerys, K. Wojcik, Wojewodzki Szpital Specjalistyczny,
Lodz; I. Mozer-Lisewska, Poznan University of Medical
Sciences, Poznan. Portugal: (L. Caldeira), Hospital Santa
Maria, Lisbon; K Mansinho, Hospital de Egas Moniz, Lis-
bon; F.Maltez, Hospital Curry Cabral, Lisbon. Romania:
(R. Radoi), C. Oprea, Victor Babes Clinical Hospital for
Infectious and Tropical Diseases, Bucharest; C. Oprea,
Carol Davila University of Medicine and Pharmacy
Bucharest. Russia: (A. Panteleev), O. Panteleev, St Peters-
burg AIDS Centre, St Petersburg; A. Yakovlev, Medical
Academy Botkin Hospital, St Petersburg; T. Trofimora,
Novgorod Centre for AIDS, Novgorod, I. Khromova, Cen-
tre for HIV/AIDS & and Infectious Diseases, Kaliningrad;
E. Kuzovatova, Nizhny Novgorod Scientific and Research
Institute of Epidemiology and Microbiology named after
Academician I. N. Blokhina, Nizhny Novogrod; E. Boro-
dulina, E. Vdoushkina, Samara State Medical University,
Samara. Serbia: (D. Jevtovic), The Institute for Infectious
and Tropical Diseases, Belgrade. Slovenia: (J. Tomazic),
University Clinical Centre Ljubljana, Ljubljana. Spain: (J.
M. Miro), M. Laguno, E. Martinez, F. Garcia, JL Blanco,
M. Martinez-Rebollar, J. Mallolas, Hospital Clinic – IDI-
BAPS University of Barcelona, Barcelona; S. Moreno,
J.M. Rodriguez, Hospital Ramon y Cajal, Madrid; B. Clo-
tet, A. Jou, R. Paredes, C. Tural, J. Puig, I. Bravo, Hospital
Germans Trias i Pujol, Badalona; P. Domingo, M. Gutier-
rez, G. Mateo, M.A. Sambeat, Hospital Sant Pau, Barce-
lona; J.M. Laporte, Hospital Universitario de Alava,
Vitoria-Gasteiz. Sweden: (K. Falconer), A. Thalme, A. Son-
nerborg, Karolinska University Hospital, Stockholm; C.J.
Treutiger, Venh€alsan-Sodersjukhuset, Stockholm; L. Flam-
holc, Malm€o University Hospital, Malm€o. Switzerland: (A
Scherrer), R. Weber, University Hospital Zurich; M. Cavas-
sini, University Hospital Lausanne; A. Calmy, University
Hospital Geneva; H. Furrer, University Hospital Bern; M.
Battegay, University Hospital Basel; P. Schmid, Cantonal
Hospital St. Gallen. Ukraine: A. Kuznetsova, Kharkov State
Medical University, Kharkov; G. Kyselyova, Crimean
Republican AIDS centre, Simferopol; M. Sluzhynska, Lviv
Regional HIV/AIDS Prevention and Control CTR, Lviv. UK:
(B. Gazzard), St. Stephen’s Clinic, Chelsea and Westminster
Hospital, London; A.M. Johnson, E. Simons, S. Edwards,
Mortimer Market Centre, London; A. Phillips, M.A.
Johnson, A. Mocroft, Royal Free and University College
Medical School, London (Royal Free Campus); C. Orkin,
Royal London Hospital, London; J. Weber, G. Scullard,
Imperial College School of Medicine at St. Mary’s, London;
A. Clarke, Royal Sussex County Hospital, Brighton; C.
Leen, Western General Hospital, Edinburgh.
The following centres have previously contributed data
to EuroSIDA: Infectious Diseases Hospital, Sofia,
Bulgaria; Ho^pital de la Croix Rousse, Lyon, France; Ho^pi-
tal de la Pitie-Salpetiere, Paris, France; Unite INSERM,
Bordeaux, France; Ho^pital Edouard Herriot, Lyon, France;
Bernhard Nocht Institut f€ur Tropenmedizin, Hamburg,
Germany; 1st I. K. A Hospital of Athens, Athens, Greece;
Ospedale Riuniti, Divisione Malattie Infettive, Bergamo,
Italy; Ospedale di Bolzano, Divisione Malattie Infettive,
Bolzano, Italy; Ospedale Cotugno, III Divisione Malattie
Infettive, Napoli, Italy; Derer Hospital, Bratislava,
Slovakia; Hospital Carlos III, Departamento de Enfer-
medades Infecciosas, Madrid, Spain; Kiev Centre for
AIDS, Kiev, Ukraine; Luhansk State Medical University,
Luhansk, Ukraine; Odessa Region AIDS Center, Odessa,
Ukraine.
Steering Committee: I. Karpov, M. Losso, J. Lundgren,
J. Rockstroh, I. Aho, L.D. Rasmussen, V. Svedhem, G.
Wandeler, C. Pradier, N. Chkhartishvili, R. Matulionyte, C.
Oprea, J.D. Kowalska, J. Begovac, J. Miro, G. Guaraldi
and R. Paredes. Chair: J. Rockstroh. Study Co-leads: A.
Mocroft and O. Kirk.
Coordinating Centre Staff: O. Kirk, L. Peters, A.
Bojesen, D. Raben, D. Kristensen, K. Laut, J.F. Larsen, D.
Podlekareva and B. Nykjær.
Statistical Staff: A. Mocroft, A. Phillips, A. Cozzi-Lepri,
S. Amele and A P.elchen-Matthews.
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